综合分析了三项药理动力学研究,比较了生物类似药MB02和参考贝瓦西祖马布
B Miguel-Lillo1, Sara Sánchez-Vidaurre1, L Pérez Díaz1
1Medical Department, mAbxience Research S.L., Madrid, Spain.
Pharmacology research & perspectives
|November 3, 2023
概括
生物类似的MB02在健康受试者中证明了与参考贝瓦齐祖马布的生物等价性. 这项分析证实了类似的安全性和免疫性概况,支持其作为治疗替代品的使用.
科学领域:
- 药理动力学和生物相似性评估
- 单克隆抗体治疗方法 单克隆抗体治疗方法
- 免疫性和安全性评估评估.
背景情况:
- 贝瓦西祖马布是癌症治疗中的关键单克隆抗体.
- 生物类似单克隆抗体的开发需要强有力的可比性证据.
- 有限的研究存在于生物类似的贝瓦齐祖马布,需要进一步的研究.
研究的目的:
- 提供强有力的证据,证明生物类似物MB02与参考贝瓦西祖马布之间的生物等价性.
- 评估和比较MB02和参考贝瓦西祖马布的安全性和免疫性概况.
- 为了支持MB02作为生物类似药的临床实用性.
主要方法:
- 在健康受试者身上进行的三项独立的药理动力学 (PK) 研究的综合分析.
- 单剂量,双盲,三臂,并行组设计,比较MB02与欧盟和美国的贝瓦西祖马布.
- 主要终点:Cmax,AUC0-∞,AUC0-t;次要终点:安全性和免疫性;使用蛋白质校正进行敏感性分析.
主要成果:
- 所有主要的药物动力学参数 (Cmax,AUC) 都显示出生物等价性,点估计和90%的置信区间在80%-125%的范围内.
- 蛋白质校正的PK参数证实了所有对对比的生物等价性.
- 发现MB02和参考贝瓦西祖马布的安全性和免疫性概况是相似的.
结论:
- 聚合的PK数据强烈支持生物类似物MB02与欧盟和美国参考贝瓦西祖马布的生物等价性.
- 在MB02和参考贝瓦西祖马布之间没有观察到临床上显著的安全性或免疫性差异.
- 这些发现强化了MB02作为生物类似疗法选择的适用性.
相关概念视频
01:16Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
133
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
133
01:12Analysis of Population Pharmacokinetic Data
267
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
267
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
68
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
68